REGN•benzinga•
Jefferies Upgrades Regeneron Pharmaceuticals: Here's What You Need To Know
Summary
Jefferies upgraded its rating of Regeneron Pharmaceuticals (NASDAQ:REGN) to Hold with a price target of $675.00, changing its price target from $536.00 to $675.00. Shares of Regeneron Pharmaceuticals are trading up 4.39% over the last 24 hours, at $739.99 per share.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 9, 2022 by benzinga